tradingkey.logo

QuidelOrtho Corp

QDEL
33.645USD
+0.135+0.40%
收盤 01/09, 16:00美東報價延遲15分鐘
2.28B總市值
虧損本益比TTM

QuidelOrtho Corp

33.645
+0.135+0.40%

關於 QuidelOrtho Corp 公司

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

QuidelOrtho Corp簡介

公司代碼QDEL
公司名稱QuidelOrtho Corp
上市日期Feb 01, 1991
CEOBlaser (Brian J)
員工數量6600
證券類型Ordinary Share
年結日Feb 01
公司地址9975 Summers Ridge Road
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92121
電話18585521100
網址https://www.quidelortho.com/
公司代碼QDEL
上市日期Feb 01, 1991
CEOBlaser (Brian J)

QuidelOrtho Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9215.00%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+4929.00%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+14410.00%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+2632.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+5650.00%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+750.00%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
+11451.00%
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
+2523.00%
Dr. Mary Lake Polan, M.D., Ph.D.
Dr. Mary Lake Polan, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9215.00%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+4929.00%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+14410.00%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+2632.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+5650.00%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+750.00%

收入明細

單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Labs
373.80M
53.41%
Point-of-Care
164.60M
23.52%
Immunohematology
142.00M
20.29%
Donor Screening
14.70M
2.10%
Molecular Diagnostic Solutions
4.80M
0.69%
地區USD
名稱
營收
佔比
North America
381.40M
54.49%
Other
142.10M
20.30%
EMEA
91.80M
13.12%
China
84.60M
12.09%
業務
地區
業務USD
名稱
營收
佔比
Labs
373.80M
53.41%
Point-of-Care
164.60M
23.52%
Immunohematology
142.00M
20.29%
Donor Screening
14.70M
2.10%
Molecular Diagnostic Solutions
4.80M
0.69%

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
其他
45.52%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
其他
45.52%
股東類型
持股股東
佔比
Investment Advisor
68.41%
Investment Advisor/Hedge Fund
35.84%
Hedge Fund
14.73%
Research Firm
2.25%
Pension Fund
1.07%
Individual Investor
0.95%
Private Equity
0.76%
Bank and Trust
0.61%
Sovereign Wealth Fund
0.52%

機構持股

更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
652
84.39M
124.22%
-20.78M
2025Q3
656
79.44M
116.95%
-23.17M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
11.01M
16.21%
-124.03K
-1.11%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
9.32M
13.72%
+39.16K
+0.42%
Sep 30, 2025
The Vanguard Group, Inc.
7.60M
11.19%
-165.71K
-2.13%
Sep 30, 2025
Rubric Capital Management LP
4.64M
6.83%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
4.44M
6.54%
+1.89M
+73.81%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
2.86M
4.21%
+350.64K
+13.98%
Sep 30, 2025
Newtyn Management, LLC
2.70M
3.97%
+994.33K
+58.30%
Sep 30, 2025
State Street Investment Management (US)
2.67M
3.93%
-32.20K
-1.19%
Sep 30, 2025
Invesco Advisers, Inc.
2.66M
3.92%
+1.33M
+100.02%
Sep 30, 2025
American Century Investment Management, Inc.
2.12M
3.11%
+199.91K
+10.44%
Sep 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
State Street SPDR S&P Health Care Equipment ETF
1.75%
Invesco S&P SmallCap Health Care ETF
1.12%
Ballast Small/Mid Cap ETF
0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
State Street SPDR S&P 600 Small Cap Value ETF
0.26%
Avantis US Small Cap Value ETF
0.26%
iShares S&P Small-Cap 600 Value ETF
0.25%
iShares U.S. Medical Devices ETF
0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
0.19%
查看更多
State Street SPDR S&P Health Care Equipment ETF
佔比1.75%
Invesco S&P SmallCap Health Care ETF
佔比1.12%
Ballast Small/Mid Cap ETF
佔比0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
佔比0.56%
JPMorgan Fundamental Data Science Small Core ETF
佔比0.35%
State Street SPDR S&P 600 Small Cap Value ETF
佔比0.26%
Avantis US Small Cap Value ETF
佔比0.26%
iShares S&P Small-Cap 600 Value ETF
佔比0.25%
iShares U.S. Medical Devices ETF
佔比0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
佔比0.19%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

QuidelOrtho Corp的前五大股東是誰?

QuidelOrtho Corp的前五大股東如下:
T. Rowe Price Investment Management, Inc.
持有股份:11.01M
佔總股份比例:16.21%。
BlackRock Institutional Trust Company, N.A.
持有股份:9.32M
佔總股份比例:13.72%。
The Vanguard Group, Inc.
持有股份:7.60M
佔總股份比例:11.19%。
Rubric Capital Management LP
持有股份:4.64M
佔總股份比例:6.83%。
Fidelity Management & Research Company LLC
持有股份:4.44M
佔總股份比例:6.54%。

QuidelOrtho Corp的前三大股東類型是什麼?

QuidelOrtho Corp 的前三大股東類型分別是:
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

有多少機構持有QuidelOrtho Corp(QDEL)的股份?

截至2025Q4,共有652家機構持有QuidelOrtho Corp的股份,合計持有的股份價值約為84.39M,占公司總股份的124.22% 。與2025Q3相比,機構持股有所增加,增幅為7.27%。

哪個業務部門對QuidelOrtho Corp的收入貢獻最大?

在FY2025Q3,Labs業務部門對QuidelOrtho Corp的收入貢獻最大,創收373.80M,占總收入的53.41% 。
KeyAI